MétaCan
Menu
Back to cohort

P-136 Attainment of Steroid-Free Clinical Remission and Normal Growth Among Canadian Children with Inflammatory Bowel Disease

2014· article· en· W2318534002 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.
aboutThe title or abstract carries a Canadian signal from the geographic lexicon.

Bibliographic record

VenueInflammatory Bowel Diseases · 2014
Typearticle
Languageen
FieldMedicine
TopicMicroscopic Colitis
Canadian institutionsUniversity of AlbertaCentre Hospitalier Universitaire Sainte-JustineChildren's Hospital Research Institute of ManitobaBC Children's HospitalInstitute for Clinical Evaluative SciencesChildren's Hospital of Eastern OntarioUniversity of OttawaHospital for Sick Children
Fundersnot available
KeywordsMedicineInflammatory bowel diseaseUlcerative colitisInternal medicineCrohn's diseaseDiseaseAmbulatoryGastroenterology

Abstract

fetched live from OpenAlex

Avoidance of chronic corticosteroid therapy is an accepted measure of quality IBD care. As part of quality improvement initiatives, the newly formed C.H.I.L.D. Foundation/CIHR Canadian Children IBD Network undertook to ascertain current rates of corticosteroid free clinical remission (SFR) and normal linear growth among Canadian children and adolescents with established ulcerative colitis (UC) and Crohn's disease (CD). During 8 weeks at participating Network sites, data were prospectively collected at consecutive ambulatory clinic visits on all patients (aged 2 to 17.9 years) with diagnosed IBD for ≥12 months. Physicians completed a brief data collection form including demographic data; IBD subtype; month/year of diagnosis; current medications; PCDAI (for CD) or PUCAI (for UC); categorical Physician Global Assessment (PGA) of current disease activity and of clinical symptom pattern in prior 6 months; any systemic steroid exposure during prior 6 months; appraisal of linear growth pattern during prior 12 months. Statistical analyses were performed using Chi-square and Mann-Whitney U tests. Five hundred seventeen patients with IBD (CD: 68%; UC: 25%; IBD-U: 7%) diagnosed >12 months were reviewed at 6 participating sites across 5 provinces. Median disease duration was 37mths (IQR 23–56). CD/UC ratios at individual sites ranged from 1.5 to 6.3. Median ages were 15.3 and 13.6 years for CD and UC respectively (P < 0.001). Sixty-four percent of CD patients and 49% of UC patients were male (chi sq P < 0.001). Based on PGA on day of visit, 73% of CD patients and 74% of UC patients had inactive disease, whereas 6% and 5%, respectively, had moderately/severely active IBD. Similarly, PCDAI and PUCAI scores were <10 in 82% of CD patients and 81% of UC patients. Nine percent of CD versus 5% of UC patients had height velocity less than -2 SD for age. Categorical assessment of disease activity patterns over the preceding 6 months (continuously quiescent in 58%, minimal activity in 27%) was also similar for CD and UC. In the preceding 6 months, 53% of patients (54% for CD; 50% for UC) were in corticosteroid-free remission (SFR) (defined as continuous absence of symptoms and normal laboratory markers of inflammation without any systemic corticosteroid exposure) and had a normal for age height velocity. The table lists corticosteroid exposure and maintenance therapy. CD and UC patients required a different therapeutic approach to achieve these similar rates of SFR (* indicates CD versus UC, P < 0.05). After at least the first year of diagnosed IBD, corticosteroid use is minimized by Canadian pediatric gastroenterologists through considerable use of biologic agents (particularly in CD) and immunomodulators. Use of 5-ASA/sulfasalazine in CD and UC appears to follow evidence-based guidelines. Although rates of sustained corticosteroid free remission with normal growth are similar for CD and UC, only in UC is this frequently achieved without immunomodulators or biologics.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.239
Teacher spread0.232 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it